Loss of nuclear prothymosin-α expression is associated with disease progression in human superficial bladder cancer

详细信息    查看全文

• 作者：Yuh-Shyan Tsai (1)
  Yeong-Chin Jou (2)
  Chun-Liang Tung (3)
  Chang-Te Lin (2)
  Cheng-Huang Shen (2)
  Syue-Yi Chen (5)
  Hsin-Tzu Tsai (1)
  Chen-Li Lai (1)
  Chao-Liang Wu (4)
  Tzong-Shin Tzai (1)
  
• 关键词：Bladder neoplasms ; Thymosin ; Foxp3 ; Lymphocyte ; Prognosis
• 刊名：Virchows Archiv
• 出版年：2014
• 出版时间：June 2014
• 年：2014
• 卷：464
• 期：6
• 页码：717-724
• 全文大小：
• 参考文献：1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-0 CrossRef
  2. Wu XR (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5:713-25 CrossRef
  3. Roupret M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R et al (2011) European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 59:584-94 CrossRef
  4. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ et al (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 59:1009-018 CrossRef
  5. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J et al (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59:997-008 CrossRef
  6. Liakou CI, Narayanan S, Ng Tang D, Logothetis CJ, Sharma P (2007) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun 7:10
  7. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5:615-25 CrossRef
  8. Wu CL, Shiau AL, Lin CS (1997) Prothymosin alpha promotes cell proliferation in NIH3T3 cells. Life Sci 61:2091-101 CrossRef
  9. Jiang X, Kim HE, Shu H, Zhao Y, Zhang H, Kofron J et al (2003) Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science 299:223-26 CrossRef
  10. Vareli K, Frangou-Lazaridis M, van der Kraan I, Tsolas O, van Driel R (2000) Nuclear distribution of prothymosin alpha and parathymosin: evidence that prothymosin alpha is associated with RNA synthesis processing and parathymosin with early DNA replication. Exp Cell Res 257:152-61 CrossRef
  11. Klimentzou P, Drougou A, Fehrenbacher B, Schaller M, Voelter W, Barbatis C et al (2008) Immunocytological and preliminary immunohistochemical studies of prothymosin alpha, a human cancer-associated polypeptide, with a well-characterized polyclonal antibody. J Histochem Cytochem 56:1023-031 CrossRef
  12. Wang M, Pan JY, Song GR, Chen HB, An LJ, Qu SX (2007) Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters. Eur J Surg Oncol 33:195-01 CrossRef
  13. Baxevanis CN, Gritzapis AD, Spanakos G, Tsitsilonis OE, Papamichail M (1995) Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alpha. Cancer Immunol Immunother 40:410-18 CrossRef
  14. Cordero OJ, Sarandeses C, Nogueira M (1995) Prothymosin alpha receptors on lymphocytes. J Interferon Cytokine Res 15:731-37 CrossRef
  15. Skopeliti M, Iconomidou VA, Derhovanessian E, Pawelec G, Voelter W, Kalbacher H et al (2009) Prothymosin alpha immunoactive carboxyl-terminal peptide TKKQKTDEDD stimulates lymphocyte reactions, induces dendritic cell maturation and adopts a beta-sheet conformation in a sequence-specific manner. Mol Immunol 46:784-92 CrossRef
  16. Jou YC, Tsai YS, Hsieh HY, Chen SY, Tsai HT, Chen KJ et al (2013) Plasma thymosin-alpha1 level as a potential biomarker in urothelial and renal cell carcinoma. Urol Oncol 31(8):1806-811. doi:10.1016/j.urolonc.2012.03.011 CrossRef
  17. Tzai TS, Tsai YS, Shiau AL, Wu CL, Shieh GS, Tsai HT (2006) Urine prothymosin-alpha as novel tumor marker for detection and follow-up of bladder cancer. Urology 67:294-99 CrossRef
  18. Jou YC, Tung CL, Tsai YS, Shen CH, Syue-Yi C, Shiau AL et al (2009) Prognostic relevance of prothymosin-alpha expression in human upper urinary tract transitional cell carcinoma. Urology 74:951-57 CrossRef
  19. Lin CT, Tung CL, Tsai YS, Shen CH, Jou YC, Yu MT et al (2012) Prognostic relevance of preoperative circulating CD8-positive lymphocytes in the urinary bladder recurrence of urothelial carcinoma. Urol Oncol 30:680-87 CrossRef
  20. Tsai YS, Jou YC, Lee GF, Chen YC, Shiau AL, Tsai HT et al (2009) Aberrant prothymosin-alpha expression in human bladder cancer. Urology 73:188-92 CrossRef
  21. Winerdal ME, Marits P, Winerdal M, Hasan M, Rosenblatt R, Tolf A et al (2011) Foxp3 and survival in urinary bladder cancer. BJU Int 108:1672-678 CrossRef
  22. Lukashev DE, Chichkova NV, Vartapetian AB (1999) Multiple tRNA attachment sites in prothymosin alpha. FEBS Lett 451:118-24 CrossRef
  23. Panneerselvam C, Haritos AA, Caldarella J, Horecker BL (1987) Prothymosin alpha in human blood. Proc Natl Acad Sci U S A 84:4465-469 CrossRef
  24. Dominguez F, Magdalena C, Cancio E, Roson E, Paredes J, Loidi L et al (1993) Tissue concentrations of prothymosin alpha: a novel proliferation index of primary breast cancer. Eur J Cancer 29A:893-97 CrossRef
  25. Cordero OJ, Sarandeses CS, Lopez JL, Cancio E, Regueiro BJ, Nogueira M (1991) Prothymosin alpha enhances interleukin 2 receptor expression in normal human T-lymphocytes. Int J Immunopharmacol 13:1059-065 CrossRef
  26. Su BH, Tseng YL, Shieh GS, Chen YC, Shiang YC, Wu P et al (2013) Prothymosin alpha overexpression contributes to the development of pulmonary emphysema. Nat Commun 4:1906 CrossRef
  27. Li KJ, Shiau AL, Chiou YY, Yo YT, Wu CL (2005) Transgenic overexpression of prothymosin alpha induces development of polycystic kidney disease. Kidney Int 67:1710-722 CrossRef
  28. Matsunaga H, Ueda H (2010) Stress-induced non-vesicular release of prothymosin-alpha initiated by an interaction with S100A13, and its blockade by caspase-3 cleavage. Cell Death Differ 17:1760-772 CrossRef
  29. Enkemann SA, Wang RH, Trumbore MW, Berger SL (2000) Functional discontinuities in prothymosin alpha caused by caspase cleavage in apoptotic cells. J Cell Physiol 182:256-68 CrossRef
  30. Evstafieva AG, Belov GA, Kalkum M, Chichkova NV, Bogdanov AA, Agol VI et al (2000) Prothymosin alpha fragmentation in apoptosis. FEBS Lett 467:150-54 CrossRef
  31. Skopeliti M, Voutsas IF, Klimentzou P, Tsiatas ML, Beck A, Bamias A et al (2006) The immunologically active site of prothymosin alpha is located at the carboxy-terminus of the polypeptide. Evaluation of its in vitro effects in cancer patients. Cancer Immunol Immunother 55:1247-257 CrossRef
  32. Olsson CA, Rao CN, Menzoian JO, Byrd WE (1972) Immunologic unreactivity in bladder cancer patients. J Urol 107:607-09
  33. Loskog A, Ninalga C, Paul-Wetterberg G, de la Torre M, Malmstrom PU, Totterman TH (2007) Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol 177:353-58 CrossRef
  
• 作者单位：Yuh-Shyan Tsai (1)
  Yeong-Chin Jou (2)
  Chun-Liang Tung (3)
  Chang-Te Lin (2)
  Cheng-Huang Shen (2)
  Syue-Yi Chen (5)
  Hsin-Tzu Tsai (1)
  Chen-Li Lai (1)
  Chao-Liang Wu (4)
  Tzong-Shin Tzai (1)
  
  1. Department of Urology, College of Medicine and Hospital, National Cheng Kung University, #138, Sheng-Li Road, Tainan, 70403, Taiwan
  2. Department of Urology, Chia-Yi Christian Hospital, Chia-Yi, Taiwan
  3. Department of Pathology, Chia-Yi Christian Hospital, Chia-Yi, Taiwan
  5. Department of Medical Research, Chia-Yi Christian Hospital, Chia-Yi, Taiwan
  4. Department of Biochemistry, College of Medicine and Hospital, National Cheng Kung University, Tainan, Taiwan
  
• ISSN：1432-2307

文摘

In this paper, we report a study on the clinical relevance of prothymosin-α expression and its correlation with intratumoral Foxp3+ and CD8+ lymphocytes (Foxp3+TIL and CD8+TIL) in bladder cancer patients. We used immunohistochemical staining for prothymosin-α, Foxp3, and CD8 on 101 tumor specimens harvested by endoscopic resection. The results were correlated with clinicopathological variables and clinical outcome in bladder cancer patients, particularly in 73 patients with superficial disease, using the log-rank test and Cox proportional hazard model. Overall, of the tumors, 30?% were negative, 34?% showed nuclear, and 37?% showed cytoplasmic prothymosin-α expression. Foxp3+TILs were detected in 11?% of patients (nonnuclear vs. nuclear, p--.096). Patients with a history of urothelial carcinoma have a higher frequency of nonnuclear prothymosin-α expression than those without (p--.016, chi-square test). By univariate and multivariate analyses of cases with superficial disease, grade and stage were identified as independent predictors for recurrence-free survival (p--.016 and 0.016, respectively). Higher stage and nonnuclear prothymosin-α expression independently predict shorter progression-free survival (p--.006 and 0.043, respectively). The presence of Foxp3+TILs was significantly associated with disease progression by univariate analysis (p--.022), but not by multivariate analysis (p--.147). In vitro assays showed that J82 cells which express ectopically nuclear prothymosin-α exhibit higher growth rate and secrete less TGF-β1 than those with cytoplasmic expression or control cells. Altogether, prothymosin-α expression is a determinant of disease progression in superficial bladder cancer. Foxp3+TILs tend to be found more often in bladder cancer with nonnuclear prothymosin-α expression. Future study is required to unravel their interaction.